Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zostavax safety and immunogenicity in adults with a history of herpes zoster
NCT00322231Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2006
- Primary completion
- Jul 2007
- Modality
- Live Attenuated Vaccines
01
Overview
Phase 3, randomised, double-blind trial of varicella virus vaccine live in herpes zoster (HZ) (2 arms), sponsored by Merck & Co. Primary endpoint: Vaccine-related Serious Adverse Experiences at 28 days. Started May 2006; status: completed.
02
Drugs
varicella virus vaccine live
03
Conditions
herpes zoster (HZ)
Beyond the preview
Go deeper on NCT00322231.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00322231.